Humana Inc. (NYSE:HUM) Shares Sold by United Capital Financial Advisors LLC

United Capital Financial Advisors LLC lowered its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 34.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,315 shares of the insurance provider's stock after selling 1,721 shares during the quarter. United Capital Financial Advisors LLC's holdings in Humana were worth $841,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of HUM. Virtu Financial LLC purchased a new position in shares of Humana in the 3rd quarter worth about $631,000. Wilmington Savings Fund Society FSB purchased a new position in Humana in the third quarter valued at approximately $948,000. Tidal Investments LLC lifted its position in Humana by 38.4% during the third quarter. Tidal Investments LLC now owns 24,357 shares of the insurance provider's stock valued at $7,715,000 after buying an additional 6,755 shares in the last quarter. Synovus Financial Corp grew its stake in Humana by 4.1% during the third quarter. Synovus Financial Corp now owns 2,254 shares of the insurance provider's stock worth $714,000 after buying an additional 89 shares during the period. Finally, Oddo BHF Asset Management Sas acquired a new stake in shares of Humana in the third quarter worth $1,306,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Stock Performance

Shares of Humana stock traded up $4.76 on Wednesday, reaching $263.68. 1,092,427 shares of the company were exchanged, compared to its average volume of 1,757,224. The firm has a market cap of $31.82 billion, a price-to-earnings ratio of 26.50, a P/E/G ratio of 2.05 and a beta of 0.62. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The company's 50-day moving average is $265.74 and its two-hundred day moving average is $270.19.

Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, research analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.34%. The ex-dividend date of this dividend is Friday, June 27th. Humana's dividend payout ratio (DPR) is 35.58%.

Analyst Ratings Changes

Several research firms recently weighed in on HUM. Mizuho lifted their target price on shares of Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. JPMorgan Chase & Co. decreased their target price on Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a research report on Tuesday, February 18th. Guggenheim assumed coverage on Humana in a report on Wednesday, April 9th. They set a "buy" rating and a $326.00 target price on the stock. Cantor Fitzgerald restated a "neutral" rating and issued a $290.00 price target on shares of Humana in a report on Wednesday, February 12th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $283.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Seventeen equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $284.90.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.